Abstract
Minimal residual disease (MRD) in multiple myeloma (MM) is evaluated by multiparametric flow cytometry (MFC), next generation sequencing (NGS), and positron emission tomography (PET-CT). MRD negativity is associated with improved survival, but there is no consensus on its value, modality, and timing. We surveyed MM clinicians regarding MRD measurement in MM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
